AWS cut drug development from months to 3 weeks: How AI agent Kiro accelerates research

Developing new drugs is a lengthy and resource-intensive process, often taking months or even years due to the vast amounts of data and complexity of research. AWS demonstrated how their AI agent Kiro can shorten this cycle to just three weeks by automating the identification of targets for new drugs, significantly accelerating R&D.

In pharmaceuticals and biotech, where every day of delay means lost opportunities and billions, accelerating research is critical. Message our manager — he will run a free analysis of your business and niche and show exactly how to get a real business result from an AI agent in your case, not a nice-looking picture. Message the manager

The Bottleneck in New Drug Target Identification

Target identification is a critically important stage in drug development, where scientists search for molecules or biological pathways that can serve as targets for a new drug. This process requires analyzing a huge amount of diverse data:

• clinical trials,
• genomic sequences,
• protein pathway databases,
• scientific literature (e.g., PubMed, where approximately 1.5 million articles are published annually).

Researchers are physically unable to read and process such a volume of information, creating a significant "bottleneck" and delaying the market entry of new drugs.

How the Kiro AI Agent Solves the Problem

AWS developed an AI agent for target identification that not only extracts relevant information but also analyzes it from various sources, identifies patterns, and provides evidence-based recommendations. This allows scientists to verify and use the obtained data for decision-making.

Kiro's implementation goals:

• Unifying fragmented knowledge. The agent collects information from PubMed, ClinicalTrials.gov, and other public repositories.
• Maintaining scientific rigor. Provides cited summaries and links to sources to preserve research integrity.
• Democratizing computational tools. Makes complex calculations accessible to biologists without specialized data engineering skills.

Spec-Driven Development Methodology

The key to rapidly creating the AI agent was the Spec-Driven Development methodology. Instead of "vibe coding" (intuitive development), Kiro creates three main documents based on an initial prompt:

1. requirements.md. Defines what is being built, including feature requirements, acceptance criteria, and success metrics.
2. design.md. Outlines the technical architecture, implementation approach, and integration points.
3. tasks.md. Breaks down the design into specific, actionable implementation steps.

This approach allows Kiro to autonomously implement features while developers focus on review and validation. It also simplifies the onboarding of new team members and accelerates the development of subsequent features, as Kiro can use previous implementations as a baseline.

Results and Prospects

Thanks to the Kiro AI agent, AWS managed to reduce the development time for a working target identification system from several months to three weeks, employing only three developers. This demonstrates that rapid AI agent development is possible even in complex fields like pharmaceuticals.

The Kiro AI agent not only accelerates R&D but also allows for:

• Significantly reducing time-to-market for drugs.
• Lowering research costs.
• Increasing data accuracy and reliability.

Source: aws.amazon.com

Want to know how AI agents can accelerate your business processes? Message the manager. We will analyze your case for free and suggest the optimal solution.